Scott M. Rocklage started working for 5AM ventures as a partner in 2003 and later became the Managing Partner. He is a personality who has over 30 years of experience in healthcare management involving strategic leadership responsibilities.
He has also served as Chairman and Chief operating officer of Cubist pharmaceuticals, Nycomed Salutar. He has also worked with Salutar and Novira in Research and Development.
Currently, he serves as the Board Chairman of Kenistral Rennovia and Cidara. The other boards that he has also served include Pulmatrix and Epirus. He was formerly the Executive Chairman of Miikana, IIypsa, and Semprus. Academically, he has a B.S. in Chemistry from the University of California and a Chemistry Ph.D from MIT. He is associated with the invention and co-inventions of over 30 US patents with over one hundred peer-reviewed publications.
5AM ventures is a science based venture capital firm that is run by Rocklage on a daily basis. He works with entrepreneurs in the field of science and medicine, and helps to refine their ideas to create real medicines to treat people. His area of expertise involves the development of medicine capable of containing cancer.
He mainly focuses on particular genotypes or mutations in his quest to providing cancer treatment in a unique way. His contributions to medicine have been able to save and extend the lives of many people. He pays special attention to time management, prioritization, and calendaring. Read more: Scott Rocklage | LinkedIn and Idea Mensch | Scott Rocklage
He is known for staying true to medicine as a profession and through his various contributions in this field. He was involved with entering six drug candidates for clinical trials. FDA approved three of his applications for new drugs. 5AM ventures, which he runs, is a firm that focuses on startup companies involving the media to provide equity.
It is involved in the business of buying shares from such companies to improve their capital transactions to get advertising space. It is currently headquartered in Paris, France.
Scott is currently involved in philanthropic activities by contributing to political agendas and several companies. He was also involved in contributions towards the development and renovation of nanotechnology laboratories